Novartis & Voyager Therapeutics inked a deal to develop gene therapies for Huntington’s and SMA

Описание: Novartis and Voyager Therapeutics have struck a licensing deal that will see Novartis pay Voyager $100 million upfront to develop gene therapy candidates targeting Huntington’s disease (HD) and spinal muscular atrophy (SMA). The total value of the deal could reach $1.2 billion with milestone payments and tiered royalties on global sales of products developed using Voyager’s proprietary capsid technology platform.

#shorts #genetherapy #rarediseases